Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
6/6/23 BridgeBio (BBIO) Truseltiq for Gastric Cancer Subscribers Only Subscribers Only Subscribers Only
6/6/23 AstraZeneca (AZN) Nirsevimab for Respiratory Syncytial Virus (RSV) Prevention Subscribers Only Subscribers Only Subscribers Only
6/5/23 Akero Therapeutics (AKRO) Efruxifermin for Non-Alcoholic Steatohepatitis (NASH) Subscribers Only Subscribers Only Subscribers Only
6/5/23 Innovent Biologics (1801) Sintilimab for Nasopharyngeal Cancer Subscribers Only Subscribers Only Subscribers Only
6/5/23 Ultragenyx (RARE) UX143 for Osteogenesis Imperfecta (OI) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
06/09/23 Subscribers Only Subscribers Only Trial Data - Top-Line Results
06/09/23 Subscribers Only Subscribers Only Regulatory - FDA Advisory Panel Meeting
06/09/23 Subscribers Only Subscribers Only Trial Data - Top-Line Results
06/09/23 Subscribers Only Subscribers Only Trial Data - Top-Line Results
06/09/23 Subscribers Only Subscribers Only Trial Data - Top-Line Results
Back to the top Back to the top